Table 2.

Antitumor activity

	Global population		Japanese population
	Nivolumab	Everolimus	Nivolumab	Everolimus
	N = 410	N = 411	N = 37	N = 26
ORR, n (%)	105 (26)	22 (5)	16 (43)	2 (8)
P value	<0.0001		Not applicable
Best overall response, n (%)
Complete response	3 (1)	2 (1)	0 (0)	1 (4)
Partial response	102 (25)	20 (5)	16 (43)	1 (4)
Stable disease	138 (34)	230 (56)	15 (40)	20 (77)
Progressive disease	143 (35)	113 (28)	6 (16)	4 (15)
Unable to determine	24 (6)	46 (11)	0 (0)	0 (0)
Median duration of response, months (95% CI)	12.0 (9.1–18.2)	12.0 (6.4–21.7)	13.4 (2.2–25.8)	NR (12.0–NR)

CI, confidence interval; NR, not reached; ORR, objective response rate.